Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I PET receptor occupancy study of pipamperone in healthy subjects
NL-OMON34843Phase 1Active, not recruiting
- Sponsor
- PharmaNeuroBoost
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pipamperone in major depressive disorder (MDD), sponsored by PharmaNeuroBoost. Primary endpoints: 5-HT2A receptor occupancy and D2 receptor occupancy. Started Dec 2009; status: active, not recruiting.
02
Drugs
pipamperone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON34843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34843.